approval
saveKESIMPTA (OFATUMUMAB) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 1, 2026 · 187d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 18, 2025 · 413d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 12, 2024 · 906d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalJan 19, 2024 · 990d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalSep 2, 2022 · 1494d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 20, 2020 · 2237d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 30, 2016 · 3688d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalJan 19, 2016 · 3912d ago
same company · ±60 days · 6
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalMay 8, 2014
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalMay 8, 2014
- approvalImatinib Mesylate Shilpa: GLEEVEC (IMATINIB MESYLATE) — FDA approvalMay 22, 2014
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalFeb 28, 2014
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalJun 6, 2014
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalJun 6, 2014
comments(0)
5-min edit window · permanent after that